Project Details
Description
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)
| Status | Active |
|---|---|
| Effective start/end date | 9/1/24 → 8/31/35 |
Funding
- DIMERIX BIOSCIENCE PTY LTD
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.